Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imidapril

Next Previous
Drug Profile

Imidapril

Alternative Names: Novarok; SH 6366; TA 6366; Tanatril

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Developer G.L. Pharma; Gerolymatos Group; Mitsubishi Tanabe Pharma Corporation; Trinity-Chiesi Pharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Imidazolidines; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diabetic nephropathies

Highest Development Phases

  • Marketed Diabetic nephropathies; Hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 03 Aug 2005 Xanodyne Pharmaceuticals has acquired the pharmaceutical assets of aaiPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top